Scinai Immunotherapeutics Business Summary

Scinai Immunotherapeutics Ltd. (SCNI) operates a dual-pillar business model centered on its boutique Contract Development and Manufacturing Organization (CDMO), Scinai Bioservices, and an internal R&D pipeline targeting inflammation and immunology (I&I). Revenue is primarily generated through fee-for-service contracts for biological process development, cGMP manufacturing, and analytical services, alongside non-dilutive grants from the Israel Innovation Authority (IIA). Following the February 2026 acquisition of Recipharm Israel, the company has integrated small-molecule API development and robotic aseptic fill-and-finish capabilities into its service suite. Scinai competes with biopharmaceutical firms like Soligenix, Phio Pharmaceuticals, and Tempest Therapeutics, positioning itself as a specialized, agile alternative for early-stage biotech startups. It leverages a proprietary alpaca-derived nanosized VHH antibody (NanoAb) platform to provide niche expertise in complex biologics that larger-scale CDMOs typically do not prioritize. The executive team is led by CEO Amir Reichman, a former GSK Vaccines and Novartis executive with extensive experience in global supply chain and engineering. He is supported by COO Elad Mark, a principal process engineer with 15 years of biotech experience, and CFO Uri Ben-or, who manages the firm's financial operations and strategic capital agreements with Yorkville Advisors. The scientific core is directed by CSO Dr. Tamar Ben-Yedidia, a 30-year immunology veteran whose background includes vaccine design at the Weizmann Institute. Scinai’s governance and strategy are bolstered by a Scientific Advisory Board including Prof. Michael Schön and Dr. Jonathan Sadeh, with institutional support from the IIA and XTX Topco Ltd. This leadership group combines deep multinational pharmaceutical pedigree with specialized academic research to drive the company’s transition from a pure-play R&D firm to a diversified, revenue-generating CDMO.